These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19010846)

  • 1. Preferential tumor targeting and selective tumor cell cytotoxicity of 5-[131/125I]iodo-4'-thio-2'-deoxyuridine.
    Morgenroth A; Deisenhofer S; Glatting G; Kunkel FH; Dinger C; Zlatopolskiy B; Vogg AT; Kull T; Reske SN
    Clin Cancer Res; 2008 Nov; 14(22):7311-9. PubMed ID: 19010846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 123I-ITdU-mediated nanoirradiation of DNA efficiently induces cell kill in HL60 leukemia cells and in doxorubicin-, beta-, or gamma-radiation-resistant cell lines.
    Reske SN; Deisenhofer S; Glatting G; Zlatopolskiy BD; Morgenroth A; Vogg AT; Buck AK; Friesen C
    J Nucl Med; 2007 Jun; 48(6):1000-7. PubMed ID: 17504875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Auger electron emitter against multiple myeloma--targeted endo-radio-therapy with 125I-labeled thymidine analogue 5-iodo-4'-thio-2'-deoxyuridine.
    Morgenroth A; Dinger C; Zlatopolskiy BD; Al-Momani E; Glatting G; Mottaghy FM; Reske SN
    Nucl Med Biol; 2011 Oct; 38(7):1067-77. PubMed ID: 21982576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodistribution, cellular uptake and DNA-incorporation of the 2'-fluoro stabilized 5-iodo-2'-deoxyuridine analog 5-iodo-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil (FIAU).
    Morgenroth A; Deisenhofer S; Neininger M; Vogg AT; Glatting G; Kull T; Reske SN
    Q J Nucl Med Mol Imaging; 2008 Sep; 52(3):305-16. PubMed ID: 18432182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale of 5-(125)I-iodo-4'-thio-2'-deoxyuridine as a potential iodinated proliferation marker.
    Toyohara J; Hayashi A; Sato M; Tanaka H; Haraguchi K; Yoshimura Y; Yonekura Y; Fujibayashi Y
    J Nucl Med; 2002 Sep; 43(9):1218-26. PubMed ID: 12215562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.
    Gibbs DD; Theti DS; Wood N; Green M; Raynaud F; Valenti M; Forster MD; Mitchell F; Bavetsias V; Henderson E; Jackman AL
    Cancer Res; 2005 Dec; 65(24):11721-8. PubMed ID: 16357184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breaking the invulnerability of cancer stem cells: two-step strategy to kill the stem-like cell subpopulation of multiple myeloma.
    Morgenroth A; Vogg AT; Zlatopolskiy BD; Siluschek M; Oedekoven C; Mottaghy FM
    Mol Cancer Ther; 2014 Jan; 13(1):144-53. PubMed ID: 24174494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and metabolism of 5-125I-iodo-4'-thio-2'-deoxyuridine in rodents.
    Toyohara J; Gogami A; Hayashi A; Yonekura Y; Fujibayashi Y
    J Nucl Med; 2003 Oct; 44(10):1671-6. PubMed ID: 14530485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of locoregional delivery of radiolabeled iododeoxyuridine and thymidylate synthase inhibitor in a hepatoma model.
    Chi KH; Wang HE; Chen FD; Chao Y; Liu RS; Chou SL; Wang YS; Yen SH
    J Nucl Med; 2001 Feb; 42(2):345-51. PubMed ID: 11216535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective, tumor-selective dual pathway activation of 5-fluoro-2'-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755.
    Boothman DA; Briggle TV; Greer S
    Cancer Res; 1987 May; 47(9):2344-53. PubMed ID: 2436761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y
    Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual addressing of thymidine synthesis pathways for effective targeting of proliferating melanoma.
    Miran T; Vogg ATJ; El Moussaoui L; Kaiser HJ; Drude N; von Felbert V; Mottaghy FM; Morgenroth A
    Cancer Med; 2017 Jul; 6(7):1639-1651. PubMed ID: 28608446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predisposition of [125I]5-iodo-2'-deoxyuridine-labeled normal and neoplastic mouse fibroblasts to lysis by normal macrophages.
    Evans R; Eidlen DM
    J Natl Cancer Inst; 1983 Nov; 71(5):983-9. PubMed ID: 6580500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine.
    Dupertuis YM; Vazquez M; Mach JP; De Tribolet N; Pichard C; Slosman DO; Buchegger F
    Cancer Res; 2001 Nov; 61(21):7971-7. PubMed ID: 11691821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of chlorotoxin for targeting of primary brain tumors.
    Soroceanu L; Gillespie Y; Khazaeli MB; Sontheimer H
    Cancer Res; 1998 Nov; 58(21):4871-9. PubMed ID: 9809993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice.
    Estella-Hermoso de Mendoza A; Campanero MA; de la Iglesia-Vicente J; Gajate C; Mollinedo F; Blanco-Prieto MJ
    Clin Cancer Res; 2009 Feb; 15(3):858-64. PubMed ID: 19188156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unlabelled iododeoxyuridine increases the rate of uptake of [125I]iododeoxyuridine in human xenografted glioblastomas.
    Dupertuis YM; Xiao WH; De Tribolet N; Pichard C; Slosman DO; Bischof Delaloye A; Buchegger F
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):499-505. PubMed ID: 11914888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase.
    Eiseman JL; Brown-Proctor C; Kinahan PE; Collins JM; Anderson LW; Joseph E; Hamburger DR; Pan SS; Mathis CA; Egorin MJ; Klecker RW
    Clin Cancer Res; 2004 Oct; 10(19):6669-76. PubMed ID: 15475457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental radionuclide therapy of HER2-expressing xenografts using two-step targeting nuclisome particles.
    Gedda L; Fondell A; Lundqvist H; Park JW; Edwards K
    J Nucl Med; 2012 Mar; 53(3):480-7. PubMed ID: 22323773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tezacitabine enhances the DNA-directed effects of fluoropyrimidines in human colon cancer cells and tumor xenografts.
    Taverna P; Rendahl K; Jekic-McMullen D; Shao Y; Aardalen K; Salangsang F; Doyle L; Moler E; Hibner B
    Biochem Pharmacol; 2007 Jan; 73(1):44-55. PubMed ID: 17046720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.